Increasing objectivity in tissue analysis

HER2 Ultralow
Detection of ultralow HER2 expression
White Paper
Ultra-sensitive detection
Detection of single photon-upconverting nanoparticle labels
Learn more
Full biomarker and morphology separation
Chromogenic counterstain and biomarker information in fully separated channels from the same sample
Learn more
Exceptional dynamic range
High-accuracy quantification based on uniform nanoparticle light quanta and a wide dynamic range detection system
Learn more
Order Now!
Limitied offer. SCIZYS Erbium kit including scanning of 10 slides
Order page

We have developed the next-generation IHC tissue analysis system, based on upconverting nanoparticles (UCNPs). The Lumito SCIZYS is a cutting-edge, high-sensitivity system combining labeling and imaging technologies to locate and measure biomarkers in tissue samples.

Press releases

2026-02-20 08:30 Lumito AB publishes year-end report 2025 Regulatory MAR
2026-02-18 09:20 Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging Regulatory
2026-02-17 15:00 Invitation to webinar in connection with Lumito AB’s year-end report for 2025 Regulatory
Read more

Lumito’s up converted nanoparticle technology, with its high sensitivity and lack of autofluorescence, makes it the ultimate method for accurate and precise quantitation of low abundance proteins in tissue sections. It is ideally placed to evaluate the role of HER2 low and ultralow expression in clinical trials such as DESTINY Breast 4, 6, 8 and 15.

Paul Warring

Director, Translational Pathology Consultation Services

This is next-gen tissue imaging. Lumito’s platform opens new doors for AI, drug development, and how we care for patients.

Jason Hipp

CEO, JD Hipp Consulting

Lumito’s technology introduces a fundamentally new approach to quantitative pathology, advancing the field well beyond the current state of the art. With the growing emphasis on precision and digital diagnostics, their innovation arrives at exactly the right moment.

Pascal Bamford

Chief Clinical Officer and Laboratory Operations, Akoya Biosciences

In some of our asthma models, we’d really been struggling with highlighting important cells such as the eosinophils. We’ve tried several different strategies, but when we finally used UCNPs for the detection of eosinophils – WOW! There they were! Easy to spot, easy to quantify. We’re convinced our customers will be as impressed as we are.

Karin von Wachenfeldt

CEO, Truly Labs AB